<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168297">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02069899</url>
  </required_header>
  <id_info>
    <org_study_id>NI-0501-05</org_study_id>
    <nct_id>NCT02069899</nct_id>
  </id_info>
  <brief_title>Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody</brief_title>
  <official_title>A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovImmune SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Supported by a grant of the 7th framework programme &quot;FP7&quot; from the European Committee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NovImmune SA</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Austria: Austrian Agency for Health and Food Safety</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Germany: Paul Ehrlich Institute</authority>
    <authority>Italy:Agenzia Italiana del Farmaco</authority>
    <authority>Spain: Spanish Agency for Medicines and Health Products</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      International, multicenter, long-term, follow-up study that will enroll HLH patients who
      have received NI-0501 in a  previous clinical trial, in the context of the clinical
      development program for NI-0501
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to monitor the long-term safety profile of patients who have
      previously received at least one dose of NI-0501, including survival at several time points
      after the administration of NI-0501.

      Moreover to study the elimination profile of NI-0501 and to assess the immunogenicity of
      NI-0501.

      Furthermore in the event that patients, upon request of the treating physician, will be
      maintained on NI-0501 treatment beyond the foreseen 8 weeks, NI-0501 safety, tolerability,
      efficacy and PK profile will be closely monitored in these patients until treatment
      discontinuation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Safety Endpoints</measure>
    <time_frame>Up to 12 months post transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>The incidence, intensity, possible relationship to NI-0501 and outcomes of adverse events, serious and non-serious, will be assessed throughout the study.
Vital signs, physical examination and laboratory values: evolution over time.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Efficacy endpoints</measure>
    <time_frame>Pre transplant, 30, 60, 100 days and 6, 12 months post transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical Response:
just before the start of conditioning and prior to Transplantation
at 30 days, 100 days, 6 months and 12 months after Transplantation
Survival:
just before the start of conditioning and prior to Transplantation
at 100 days, 6 months and 12 months after Transplantation</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Up to 6 months after last NI-0501 infusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>- NI-0501 elimination profile</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Up to 6 months after last NI-0501 infusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>IFNγ total, as long as NI-0501 can be measured
IFNγ free, as soon as NI-0501 is not detectable
Exploratory parameters/disease markers</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Up to 6 months after last NI-0501 infusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Presence of anti-drug antibodies (i.e. ADAs)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hemophagocytic Lymphohistiocytosis</condition>
  <arm_group>
    <arm_group_label>NI-0501 only in case is requested</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>NI-0501, in the event that, upon request of the treating physician, NI-0501 treatment needs to be prolonged beyond Week 8 foreseen in the previous protocol, patients will continue receiving NI-0501 in the context of this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NI-0501</intervention_name>
    <description>In the event that NI-0501 treatment needs to be prolonged beyond Week 8 foreseen in the previous study, and upon request of the treating physician, patients will continue receiving NI-0501 in the context of this study.</description>
    <arm_group_label>NI-0501 only in case is requested</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having received at least one dose of NI-0501 during a previous NI-0501 study.

          -  Having signed the Informed Consent by the patient or the patient's legal
             representative(s), as applicable, with the assent of patients who are legally capable
             of providing it.

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cristina de Min, MD</last_name>
    <phone>0041_22_593_5116</phone>
    <email>cdemin@novimmune.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alfred I. duPont Hospital for Children Nemours Center for Cancer and Blood Disorders</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonathan Powell, MD</last_name>
      <phone>302-651-5500</phone>
      <email>Jonathan.Powell@nemours.org</email>
    </contact>
    <contact_backup>
      <last_name>Debra Bertz</last_name>
      <email>Debra.Bertz@nemours.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan Powell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute (DFCI)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barbara A. Degar, MD</last_name>
      <phone>617-632-5186</phone>
      <email>Barbara_Degar@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Barbara A Degar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital - Division of Immunobiology</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Jordan, MD</last_name>
      <phone>513-636-7287</phone>
      <email>Michael.Jordan@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Michael Jordan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carl Allen, MD, PhD</last_name>
      <phone>832-824-4312</phone>
      <email>ceallen@txch.org</email>
    </contact>
    <investigator>
      <last_name>Carl Allen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Anna Children's Hospital Dept. Outpatient Hematology/Oncology</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wolfgang Holter, MD</last_name>
      <phone>0043_140_170</phone>
      <phone_ext>1250</phone_ext>
      <email>wolfgang.holter@stanna.at</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Holter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charles University Prague University Hospital Motol Department of Pediatric Hematology and Oncology</name>
      <address>
        <city>Prague</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Petr Sedlacek, MD</last_name>
      <phone>0042_0224436401</phone>
      <email>petr.sedlacek@lfmotol.cuni.cz</email>
    </contact>
    <investigator>
      <last_name>Petr Sedlacek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Münster Department of Pediatric Hematology and Oncology</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Herbert Jurgens, MD</last_name>
      <phone>0049 2518347941</phone>
      <email>jurgh@uni-muenster.de</email>
    </contact>
    <investigator>
      <last_name>Herbert Jurgens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Meyer</name>
      <address>
        <city>Florence</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Bambi, MD</last_name>
      <email>f.bambi@meyer.it</email>
    </contact>
    <investigator>
      <last_name>Franco Bambi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini - Emato-Oncologia Pediatrica</name>
      <address>
        <city>Genoa</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Concetta Micalizzi, MD</last_name>
      <phone>0039_010_5636</phone>
      <phone_ext>715</phone_ext>
      <email>concettamicalizzi@ospedale-gaslini.ge.it</email>
    </contact>
    <investigator>
      <last_name>Concetta Micalizzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo - Centro di Emato-Oncologia Pediatrica</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmelo Rizzari, MD</last_name>
      <phone>0039_039_233</phone>
      <phone_ext>3513</phone_ext>
      <email>c.rizzari@hsgerardo.org</email>
    </contact>
    <contact_backup>
      <last_name>Giusy Sgroi, MSc</last_name>
      <phone>0039_039 233</phone>
      <phone_ext>4915</phone_ext>
      <email>gsgroi@fondazionembbm.it</email>
    </contact_backup>
    <investigator>
      <last_name>Carmelo Rizzari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santobono Pausilipon</name>
      <address>
        <city>Naples</city>
        <zip>80123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmen De Fusco, MD</last_name>
      <phone>0039_081_2205410</phone>
      <email>carmendefusco@iol.it</email>
    </contact>
    <contact_backup>
      <last_name>Gaia Sepe, MSc</last_name>
      <email>gaia.sepe@hotmail.it</email>
    </contact_backup>
    <investigator>
      <last_name>Carmen De Fusco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Padova - Clinica di Oncoematologia Pediatrica</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mariacaterina Putti, MD</last_name>
      <phone>0039_049_8213535</phone>
      <email>mariacaterina.putti@unipd.it</email>
    </contact>
    <investigator>
      <last_name>Mariacaterina Putti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesu'</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Locatelli, MD</last_name>
      <phone>0039 06 68592678</phone>
      <email>franco.locatelli@opbg.net</email>
    </contact>
    <investigator>
      <last_name>Franco Locatelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Regina Margherita / S. Anna - Unità di Oncoematologia</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franca Fagioli, MD</last_name>
      <phone>0039 011 313 5259</phone>
      <email>franca.fagioli@unito.it</email>
    </contact>
    <investigator>
      <last_name>Franca Fagioli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron Servei de Hematologia i Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08900</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Sanchez de Toledo, MD</last_name>
      <phone>0034_934893093</phone>
      <email>jossanchez@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Jose Sanchez de Toledo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu Sección de Alergia e Inmunología Clínica</name>
      <address>
        <city>Barcelona - Esplugues de Llobregat</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laia Alsina, MD</last_name>
      <phone>0034_932804000</phone>
      <phone_ext>3330</phone_ext>
      <email>lalsina@hsjdbcn.org</email>
    </contact>
    <contact_backup>
      <last_name>Albert Català, MD</last_name>
      <email>acatala@hsjdbcn.org</email>
    </contact_backup>
    <investigator>
      <last_name>Laia Alsina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Cruces Servicio de Pediatria</name>
      <address>
        <city>Bilbao</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Itziar Astigarraga, MD</last_name>
      <phone>0034_946006357</phone>
      <email>itziar.astigarraga@osakidetza.net</email>
    </contact>
    <investigator>
      <last_name>Itziar Astigarraga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Niño Jesús Servicio de Hemato-Oncología Pediátrica</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alvaro Lassaletta, MD</last_name>
      <phone>0034_915035938</phone>
      <email>lassaalvaro@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Julian Sevilla, MD</last_name>
      <phone>0034_915_035</phone>
      <phone_ext>938</phone_ext>
      <email>julian.sevilla@salud.madrid.org</email>
    </contact_backup>
    <investigator>
      <last_name>Alvaro Lassaletta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julian Sevilla, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>December 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemophagocytic lymphohistiocytosis (HLH) previously treated with NI-0501</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
